This quick reference clinical tool has been written by experts in the field to support stop smoking practitioners with the task of helping clients to choose the best medication for them.
To make best use of this reference sheet, you should take the NCSCT online Stop Smoking Medications module and familiarise yourself with the Summary of Product Characteristics for each medication (available on this website in specific chapters in this STOP SMOKING AIDS section).
This briefing addresses the cost-effectiveness of smoking cessation interventions.
Analysis shows that when smoking cessation interventions are effective they are invariably also cost-effective; and that this is also the case for pharmacotherapy for smoking cessation, including nicotine replacement therapy (NRT), bupropion (Zyban) and varenicline (Champix).
Indeed, findings from economic analyses from the UK and elsewhere confirm that smoking cessation interventions, including pharmacotherapy, are among the most cost-effective health care interventions available.
Fully updated NCSCT briefing on combination NRT including the latest research evidence and clinical good practice.
The original NCSCT briefing on combination NRT was written in 2012 because, despite good evidence on safety and efficacy, obtaining support and funding for combination NRT was often difficult. Since that time, clinical experience and evidence regarding the role of combination NRT in increasing quit rates has grown and it has now been established as standard treatment.
This updated briefing is intended as a resource for commissioners, managers and staff of stop smoking services and summarises the latest evidence and practice guidance related to combination NRT.
The following documents are provided here as examples only. Local areas are welcome to adapt them further as required.